Pictilisib (GDC-0941)

Name: Pictilisib (GDC-0941)
Brand: Selleck Chemicals
SKU: S1065
Rating: 5 (307 reviews)

For research use only.

Catalog No.S1065 Synonyms: RG7321

307 publications

Pictilisib (GDC-0941) Chemical Structure

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

Selleck's Pictilisib (GDC-0941) has been cited by 307 publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cell, 2013, 7;155(4):844-57.

PubMed: 24209622 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(3):289-296

PubMed: 32094692 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2291

PubMed: 32385243 ( click the link to review the publication )

Nat Commun, 2020, 11(1):1290

PubMed: 32157087 ( click the link to review the publication )

EMBO Mol Med, 2020, e11674

PubMed: 32558386 ( click the link to review the publication )

Cell Syst, 2020, 20;10(5):384-396.e9

PubMed: 32437683 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 30(13):4584-4599

PubMed: 32234489 ( click the link to review the publication )

J Control Release, 2020, 318:98-108

PubMed: 31838203 ( click the link to review the publication )
Sci Signal, 2020, 13(637):eaba8627

PubMed: 32576681 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

Front Oncol, 2020, 1;10:393

PubMed: 32296637 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):7401

PubMed: 32366879 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):533-540

PubMed: 32565979 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

Oncotarget, 2020, 28;11(17):1493-1504

PubMed: 32391119 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )
Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

J Transl Med, 2019, 17(1):431

PubMed: 31888636 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )
Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )
Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )
Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016, 15(12):2692-704

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )
Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )
Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )
Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )
Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )
Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	Mnu3T4lv[XOnIFHzd4F6		MnSyNUBp	NFiwUFNFVVOR	NHXxW41KdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHTlcJRiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhiKHerdHigTWM2OCCxZjCwMlAxOyEQvF2=	NH\Ob3YyQDd3NE[1OC=>
Sf9	M1;VTmtqdmG\|ZTDBd5NigQ>?		NF7tTWwyKGh?	M1r5cmROW09?	MnLyTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGgyODR5LWKgcZV1[W62IHX4dJJme3OnZDDpckBU\jliY3XscJMh[2:neIDy[ZN{cW6pIIC4OYFteGijIIfpeIghUUN3MDDv[kAxNjByMzFOwG0>	MVyxPFc2PDZ3NB?=
Sf9	MmnJT4lv[XOnIFHzd4F6		M{XoOlEhcA>?	Mnf0SG1UVw>?	M1LEN2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYnX0ZUBGPTR3LVugcZV1[W62IHX4dJJme3OnZDDpckBU\jliY3XscJMh[2:neIDy[ZN{cW6pIIC4OYFteGijIIfpeIghUUN3MDDv[kAxNjByMzFOwG0>	NYPFN3FWOTh5NUS2OVQ>
Sf9	MWPLbY5ie2ViQYPzZZk>		MU[xJIg>	NUS4NWJITE2VTx?=	MnvBTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCzN{DPxE1?	M2TaPFE5PzV2NkW0
Sf9	NWfIeYtMU2mwYYPlJGF{e2G7		NIXHVoEyKGh?	Mlq0SG1UVw>?	MlLQTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCjbIDoZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHPv[ZhxemW\|c3nu[{BxQDWjbIDoZS=>	NV\oUHZsOTh5NUS2OVQ>
MDA-MB-361	MYrGeY5kfGmxbjDBd5NigQ>?		MlfJNkBp	MX3EUXNQ	NVfmUXBNUW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNSGEuVUJvM{[xJINmdGy\|IIfpeIghWEmNM1PBJGU2PDVvSzDteZRifGmxbjD3bZRpKEmFNUCgc4YhOC5yMkig{txO	Mn;ZNVg4PTR4NUS=
PC3	NYDYPHVjTnWwY4Tpc44hSXO\|YYm=		MlexNkBp	MXvEUXNQ	NEDuNGNKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDQR\|Mh[2WubIOge4l1cCCLQ{WwJI9nKDBwMEO3JO69VQ>?	NXjo[4RGOTh5NUS2OVQ>
U87MG	Mo\SSpVv[3Srb36gRZN{[Xl?		NVO1[mk3OiCq	MUfEUXNQ	NInN[WRKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wOFYh\|ryP	NYX3[WlCOTh5NUS2OVQ>
MDA-MB-361	NXL6b5B5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF3MOXI6PiCq	M4\UbGROW09?	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0{PjFiY3XscJMhf2m2aDDQTWs{S0FiRUW0OU1MKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlczKM7:TR?=	M3mzelE5PzV2NkW0
A2780	Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4nhNVk3KGh?	NYjCU3g5TE2VTx?=	MoLPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDMke4NEBk\WyuczD3bZRpKFCLS{PDRUBidmRiUGTFUkBufXSjdHnvckB4cXSqIFnDOVAhd2ZiMD6xOEDPxE1?	NWHFbFVUOTh5NUS2OVQ>
PC3	M1XiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHW0W\|I6PiCq	NXnUR2pITE2VTx?=	MUDJR\|UxRTBwMkig{txO	MnvMNVg4PTR4NUS=
U87MG	NYLic3BDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYW5OkBp	M4W2UWROW09?	M4jiNGlEPTB;MD65OUDPxE1?	M4fGdlE5PzV2NkW0
Sf9	MkPQT4lv[XOnIFHzd4F6		NEHqbXg{OCCvaX6=	MVrEUXNQ	NVzuXml7UW6qaXLpeIlwdiCxZjDoeY1idiCSSUPL[4FudWFiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJIFud3WwdDDv[kBCXFBiY3;ud5Vu\WRid3n0bEBKSzVyIH;mJFAvODR{IN88US=>	MWqyNlU1QDN2Mh?=
RAW 264.7	NWS3[oFMU2mwYYPlJGF{e2G7		Ml7XPVAhdWmw	NHfmVoFFVVOR	NFf2elZKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjJ7ODFOwG0>	NGDxW2QzOjV2OEO0Ni=>
Sf9	M1\5OmtqdmG\|ZTDBd5NigQ>?		MYWxJIg>		NFXFNlZKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[mW2YTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU1[5JINmdGy\|IIfpeIghUUN3MDDv[kAxNjBzNzFOwG0>	NIjDN\|gzOzV2ME[0OS=>
Sf9	MnnWT4lv[XOnIFHzd4F6		MlqxNUBp		MVrJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPL[IVtfGFiZYjwdoV{e2Wm	MmGxNlM2PDB4NEW=
Sf9	M2XNU2tqdmG\|ZTDBd5NigQ>?		NEDSNXgyKGh?		Mln6TY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4didW2jIHX4dJJme3OnZB?=	MVuyN\|U1ODZ2NR?=
Sf9	M3r1RmtqdmG\|ZTDBd5NigQ>?		Mn7iNUBp		NHGyO2RKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[WyyaHGg[ZhxemW\|c3Xk	M1fRZlI{PTRyNkS1
SKOV3	MmDDT4lv[XOnIFHzd4F6	MknONUDPxE1?	NFrhOGUyKGh?	MYXEUXNQ	MX7Jcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9v	MUKyN\|M3ODN2OB?=
MCF7	M4fTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfRNUDPxE1?	NG\FOoY6PiCq	MXnEUXNQ	MlPiS2k2OD1yLkC3NFIh\|ryP	M13K[\|I{OzZyM{S4
SKOV3	M{DYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3mWIcxOSEQvF2=	M4foVlk3KGh?	NHTydXFFVVOR	NFLuXI5IUTVyPUCuNVQ4PiEQvF2=	MVeyN\|M3ODN2OB?=
PC3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHq1[3k4OiCq	NHjZT5BFVVOR	NWXGdWZ{UUN3ME2wMlI5KM7:TR?=	MXKyNVk5OTdzNB?=
MCF7.1	NWHXUmRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWDNbpB7PzJiaB?=	Mmj2SG1UVw>?	MnPQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3MlEh[2WubIOg[ZhxemW\|c3nu[{BJTVJ{IHflcoUhf2m2aDDJR\|UxKG:oIECuNlgh\|ryP	NUXTbXhIOjF7OEG3NVQ>
MCF7-neo/Her2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3fDU\|czKGh?	NXT2[ZY6TE2VTx?=	Ml[xTWM2OD1yLkK5JO69VQ>?	NFrudpQzOzZ4MkmwNy=>
MCF7-neo/Her2	M3LJPGtqdmG\|ZTDBd5NigQ>?				NETieZhKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbjDheEBUPDd\|IIfpeIghUUN3MDDv[kAxNjByNzFOwG0>	NF;vcWczOzZ4MkmwNy=>
PC3	NHK5eIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXPEXFR6PzJiaB?=	MXnEUXNQ	Mm\zSWM2OD1yLkO0JO69VQ>?	M4S0SlIyQTh3NkO5
MCF7.1	M2DOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGnXZWk4OiCq	NGDtU2VFVVOR	NIDXWXlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCvdYThcpQhf2m2aDDFR\|UxKG:oIECuN\|kh\|ryP	Mn\4NlE6QDV4M{m=
PC3	M1rYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYq3NkBp	NHW3NI1FVVOR	Mn\NRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiZHXmbYNq\W62IHnuJHBVTU5id3n0bEBKSzVyIH;mJFAvOzlizszN	MnKyNlAxPTB4Nkm=
MCF7.1	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3rwW\|czKGh?	MWLEUXNQ	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCLQ{WwJI9nKDBwM{Sg{txO	M4jHblIxODVyNk[5
MCF7.1	NVi3b\|huT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXy3NkBp		M4PPOWVEPTB;MD63NkDPxE1?	NH3qeXUzODN2Nk[1Oi=>
NCI-H1975	MnHDR5l1d3SxeHnjJGF{e2G7		NHP6UVE4OiCq		MkfvTWM2OD1yLkK3JO69VQ>?	M{DJVFI{ODV7NUS1
H460	Moq3R5l1d3SxeHnjJGF{e2G7		MVK3NkBp		NIHiXHFKSzVyPUCuPFch\|ryP	NIfyOHMzOzB3OUW0OS=>
HT-29	NIjnR3dEgXSxdH;4bYMhSXO\|YYm=		NY[4SVN{PzJiaB?=		NUfndmY4UUN3ME2wMlY3KM7:TR?=	MY[yN\|A2QTV2NR?=
HepG2	NHHn[I5EgXSxdH;4bYMhSXO\|YYm=		NH;ZcWg4OiCq		M1nlemlEPTB;MTFOwG0>	MY[yN\|A2QTV2NR?=
SGC7901	NInlUYNEgXSxdH;4bYMhSXO\|YYm=		MU[3NkBp		M2G0SWlEPTB;MT64JO69VQ>?	Ml;QNlMxPTl3NEW=
NCI-H226	M{L1OGN6fG:2b4jpZ{BCe3OjeR?=		NIH2bVA4OiCq		M2Xk[mlEPTB;Mj65JO69VQ>?	MUCyN\|A2QTV2NR?=
A549	MYLDfZRwfG:6aXOgRZN{[Xl?		MX:3NkBp		MWnJR\|UxRTZwOTFOwG0>	MVuyN\|A2QTV2NR?=
U87MG	NF35WVBEgXSxdH;4bYMhSXO\|YYm=		MXm3NkBp		MXXJR\|UxRTdwN{eg{txO	M3;kS\|I{ODV7NUS1
HBC4	NFzNOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjKcI9oT0l3ME2tOk4xOyCP	NEiwW3EzOjN\|NkK0Oi=>
BSY1	M{fI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHu2RY5td2eJSUWwQU03NjlyIF2=	NInqWnozOjN\|NkK0Oi=>
HBC5	M2\2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4i2Ooxw\0eLNUC9MVYvPjBiTR?=	MVeyNlM{PjJ2Nh?=
MCF7	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnyflltd2eJSUWwQU04NjN\|IF2=	MU[yNlM{PjJ2Nh?=
MDA-MB-231	NGT1Nm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nPd4xw\0eLNUC9MVUvPDZiTR?=	NVuxOIRWOjJ\|M{[yOFY>
U251	NI\mUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;acI9oT0l3ME2tOU42OCCP	MnjuNlI{OzZ{NE[=
SF268	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHf2Omttd2eJSUWwQU02NjN7IF2=	M2TjOFIzOzN4MkS2
SF295	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXKyO4I6dG:pR1m1NF0uPi5\|NzDN	NXvO[HcxOjJ\|M{[yOFY>
SF539	NXjN[3JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfxWFR{dG:pR1m1NF0uPi53MDDN	MlXXNlI{OzZ{NE[=
SNB75	NWXhRolUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnsc4dIUTVyPT23MlExKE1?	MlfTNlI{OzZ{NE[=
SNB78	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrsc4dIUTVyPT22MlUzKE1?	MXmyNlM{PjJ2Nh?=
HCC2998	NXz0OFBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\rcI9oT0l3ME2tOk4zQSCP	NYHoNHhjOjJ\|M{[yOFY>
KM12	NV33VJhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGD2[3Ftd2eJSUWwQU02Njd4IF2=	MkTGNlI{OzZ{NE[=
HT-29	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUn3bWZZdG:pR1m1NF0uPi5\|MDDN	MUGyNlM{PjJ2Nh?=
HCT15	NWTsPVI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW[1WZRNdG:pR1m1NF0uPi5zMjDN	MkLTNlI{OzZ{NE[=
HCT116	M3HE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1m2Toxw\0eLNUC9MVUvQDdiTR?=	Moj3NlI{OzZ{NE[=
NCI-H23	NWnUT5BuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfyVoxpdG:pR1m1NF0uPS55MzDN	NUDDZ\|ZbOjJ\|M{[yOFY>
NCI-H226	NIrMcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIn5PZBtd2eJSUWwQU03NjJzIF2=	M3T0V\|IzOzN4MkS2
NCI-H522	M1jpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS4cI9oT0l3ME2tOk42QCCP	MnfGNlI{OzZ{NE[=
NCI-H483	NFXLNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLIcI9oT0l3ME2tOk42PiCP	NFrtR3ozOjN\|NkK0Oi=>
A549	NW\4eVRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHL2V2xtd2eJSUWwQU03NjF3IF2=	M{DxdFIzOzN4MkS2
DMS273	NYSzcWlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LSXYxw\0eLNUC9MVYvPDNiTR?=	M1;YclIzOzN4MkS2
DMS114	M3TnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknmcI9oT0l3ME2tOU46OiCP	MXeyNlM{PjJ2Nh?=
LOXIMVI	M{G0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17Ib4xw\0eLNUC9MVYvOjliTR?=	NXfhfY1JOjJ\|M{[yOFY>
OVCAR3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHsc4dIUTVyPT22MlcyKE1?	MWWyNlM{PjJ2Nh?=
OVCAR4	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvRS3Ntd2eJSUWwQU02Njd4IF2=	NV\OT\|RVOjJ\|M{[yOFY>
OVCAR5	M{DFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TJeYxw\0eLNUC9MVYvOjZiTR?=	NFjZ[G4zOjN\|NkK0Oi=>
OVCAR8	NVTJWI51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDGcI9oT0l3ME2tOU44OyCP	MV:yNlM{PjJ2Nh?=
SKOV3	M1TiWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PKc4xw\0eLNUC9MVYvPTJiTR?=	NXzrPFBkOjJ\|M{[yOFY>
RXF631L	M1H6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXYVYttd2eJSUWwQU03Njh6IF2=	MlXMNlI{OzZ{NE[=
ACHN	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\sc4dIUTVyPT22MlA4KE1?	NIjW[G0zOjN\|NkK0Oi=>
St-4	MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkT5cI9oT0l3ME2tOU42PiCP	MV2yNlM{PjJ2Nh?=
MKN1	NFy3bYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfocI9oT0l3ME2tO{4xQCCP	MmWxNlI{OzZ{NE[=
MKN7	NGnMV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\2NJI5dG:pR1m1NF0uPi53MDDN	M2fHcFIzOzN4MkS2
MKN28	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXsc4dIUTVyPT21MlUzKE1?	M{jrO\|IzOzN4MkS2
MKN45	M3TZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3sc4dIUTVyPT22MlU2KE1?	NI\UU48zOjN\|NkK0Oi=>
MKN74	NH60SZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWiz[YRQdG:pR1m1NF0uPi5yMjDN	MmmzNlI{OzZ{NE[=
DU145	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXLcI9oT0l3ME2tOU45PSCP	NF\DPGYzOjN\|NkK0Oi=>
PC3	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\pTWdtd2eJSUWwQU03NjZ4IF2=	MYeyNlM{PjJ2Nh?=
ES5	M4HPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTVyLkKxJI5O	Mlz5V2FPT0WU
HH	M3TrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M332WmlEPTB;MUGxMlA5KG6P	NXnXd41xW0GQR1XS
MHH-PREB-1	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETlW\|ZKSzVyPUGxOE4{KG6P	MYHTRW5ITVJ?
NCI-H1770	M3HheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTF{Mz64OkBvVQ>?	MlXqV2FPT0WU
HuO9	NGTqco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTJyNj6wNkBvVQ>?	NGrMcWpUSU6JRWK=
HAL-01	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mne4TWM2OD1{ME[uO\|Mhdk1?	NGGxW2RUSU6JRWK=
NOS-1	NVj5T5NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4j5fWlEPTB;MkGxMlgzKG6P	M3zZVHNCVkeHUh?=
HGC-27	M37CVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLKTWM2OD1{MUKuOVchdk1?	MlLvV2FPT0WU
NB69	M4j2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zoWmlEPTB;MkS1MlI4KG6P	NEnCOXdUSU6JRWK=
RS4-11	NUHyWHgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrVTWM2OD1{NkGuO\|Yhdk1?	MYDTRW5ITVJ?
DOK	NXW0VFM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDQTWM2OD1\|MEGuO{BvVQ>?	NYXz[4x1W0GQR1XS
LB2241-RCC	NG\mdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn36TWM2OD1\|MEOuPFQhdk1?	NX;TXXB7W0GQR1XS
NCI-H1623	MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDUTWM2OD1\|MESuNFghdk1?	M3T6dnNCVkeHUh?=
YH-13	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTNyND6zNkBvVQ>?	M3[4UXNCVkeHUh?=
BPH-1	NEPVVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnkU5hKSzVyPUOxOEBvVQ>?	MYPTRW5ITVJ?
AN3-CA	Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TTWWlEPTB;M{SwMlM4KG6P	NXj0UYFLW0GQR1XS
ES7	M2TCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkT2TWM2OD1\|NEGuPVkhdk1?	MkHjV2FPT0WU
MDA-MB-175-VII	MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jIZmlEPTB;M{WyMlkzKG6P	NXW1RpRYW0GQR1XS
GAMG	NHj6TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvTTWM2OD1\|N{CuPFUhdk1?	NUDoOIFzW0GQR1XS
CHL-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTN5OD62OUBvVQ>?	NVfyfGpkW0GQR1XS
NB7	Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXhTWM2OD1\|OEmuPFMhdk1?	NHPDTZBUSU6JRWK=
MFE-280	M3fVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonuTWM2OD12MUiuNkBvVQ>?	NELpbWJUSU6JRWK=
HL-60	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTR{NT63OUBvVQ>?	M1zjfHNCVkeHUh?=
GCIY	NYD3SpNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEG3XplKSzVyPUSzN{45KG6P	MVjTRW5ITVJ?
MDA-MB-361	M2D6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrKXlhiUUN3ME20N\|kvOTNibl2=	NFrTXWNUSU6JRWK=
LXF-289	Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TJVmlEPTB;NES4MlI4KG6P	M1nJWHNCVkeHUh?=
NBsusSR	NV3COIlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrHUmtqUUN3ME20PFgvQDVibl2=	NWDJXIRXW0GQR1XS
KU-19-19	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17a[GlEPTB;NUG2MlA4KG6P	Mm\pV2FPT0WU
A204	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnf0TWM2OD13MkKuN\|Mhdk1?	M{PJfHNCVkeHUh?=
LB1047-RCC	NIP1TlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvHbG57UUN3ME21NlIvQTNibl2=	M2DIdHNCVkeHUh?=
COLO-684	Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TTbmlEPTB;NUKzMlEyKG6P	NGnk[YJUSU6JRWK=
PA-1	NGjFNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXLV\|lDUUN3ME21N\|IvPDFibl2=	NESydI5USU6JRWK=
MG-63	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVKyNWE2UUN3ME21OFEvOTFibl2=	Mn3EV2FPT0WU
BHT-101	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7IXopKSzVyPUW0OE46PCCwTR?=	MV\TRW5ITVJ?
NKM-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrIVpBKSzVyPUW5N{4xQSCwTR?=	NF\uUGlUSU6JRWK=
T47D	NVrQZoVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTV7Nz61OkBvVQ>?	NG\p[GNUSU6JRWK=
MOLT-4	M2LVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTZ{Mz62NkBvVQ>?	M3LKd3NCVkeHUh?=
IGROV-1	Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnr[G1mUUN3ME22N\|QvOzFibl2=	NHS4WXVUSU6JRWK=
ES4	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTZ\|OT61OEBvVQ>?	NICwUI5USU6JRWK=
HuO-3N1	M4HGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XBXmlEPTB;NkSyMlM5KG6P	NVfRcplJW0GQR1XS
NEC8	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFn0UVRKSzVyPU[1N{42PyCwTR?=	MYTTRW5ITVJ?
HO-1-N-1	M{DkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7nfnA6UUN3ME22OVkvOTdibl2=	MYXTRW5ITVJ?
EPCL-272H	NVzqT\|RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofzTWM2OD14OEeuNlEhdk1?	MX;TRW5ITVJ?
D-263MG	NX;iS\|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7hPZRKSzVyPUexPE4yKG6P	MWnTRW5ITVJ?
MV-4-11	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTd{ND6zNUBvVQ>?	MVzTRW5ITVJ?
SK-NEP-1	NEDLbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTYTWM2OD15MkWuPVQhdk1?	NH3vS3dUSU6JRWK=
SW872	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjKVYxKSzVyPUeyO{45QSCwTR?=	NUTxV3I3W0GQR1XS
P30-OHK	NFnucm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnJbHVqUUN3ME23N\|AvPzFibl2=	M{LrN3NCVkeHUh?=
OMC-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTd3MT6wPUBvVQ>?	MnzOV2FPT0WU
LoVo	NXe0cVN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jaW2lEPTB;N{e3Mlkhdk1?	NEHNcWJUSU6JRWK=
LNCaP-Clone-FGC	NH25[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljMTWM2OD15OU[uN\|Qhdk1?	MofzV2FPT0WU
L-363	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXrVHdZUUN3ME23PVgvPDJibl2=	MoDZV2FPT0WU
ES8	M2Ttfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHq5SHJKSzVyPUixNE42OiCwTR?=	NID2RYNUSU6JRWK=
697	NVHWcoRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mor4TWM2OD16M{GuOVUhdk1?	NELIbWRUSU6JRWK=
HSC-3	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHn3ZYxKSzVyPUizPU42PCCwTR?=	MmDlV2FPT0WU
H4	M3HuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVe0TGZoUUN3ME24OVAvQDVibl2=	NFW5XI1USU6JRWK=
QIMR-WIL	NYHyclRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLvRoNQUUN3ME24OlUvOiCwTR?=	NUfNXG1nW0GQR1XS
OAW-42	MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTh5Mj6xPUBvVQ>?	MXHTRW5ITVJ?
MCF7	NXXJS4JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHtb2tiUUN3ME24PVgvPTlibl2=	NG[1WXBUSU6JRWK=
SCC-25	NGCzUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnLTWM2OD17MUSuNVkhdk1?	M1;TVHNCVkeHUh?=
NCI-H1563	M{nuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTlzNT65PUBvVQ>?	M{fHWXNCVkeHUh?=
OVCAR-5	NVy0cnF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTl2MD6xO{BvVQ>?	NXT4b\|NkW0GQR1XS
HDLM-2	NXnWdFZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mli0TWM2OD17NEmuNkBvVQ>?	NITaPJlUSU6JRWK=
NB5	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTl3Nj62JI5O	NVLkbHE2W0GQR1XS
NCI-H292	NG\uUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\XR2lEPTB;OUe0MlMzKG6P	Mm\yV2FPT0WU
A101D	NXnRWYZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTl7MD6xPUBvVQ>?	NIrNb4dUSU6JRWK=
NCI-H1648	M3rSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{m3eGlEPTB;OUm4MlUyKG6P	NGTJbIVUSU6JRWK=
EKVX	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnkTWM2OD1zLkCxNlkh\|ryP	NEL5OlNUSU6JRWK=
SW1710	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTFwMESyN\|Mh\|ryP	MlP0V2FPT0WU
WM-115	M2jxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfCSWt6UUN3ME2xMlA3PjV4IN88US=>	NVjQXJl6W0GQR1XS
CAL-54	NH71[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4e2RWlEPTB;MT6wO\|A5OSEQvF2=	MYLTRW5ITVJ?
TGBC24TKB	NX71XlRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTFwMEiwOFUh\|ryP	MXfTRW5ITVJ?
NCI-H520	NWHDe285T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fV[WlEPTB;MT6wPFk3PyEQvF2=	M33PbHNCVkeHUh?=
D-423MG	MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvxWG1tUUN3ME2xMlA6QTZ{IN88US=>	M{LGVnNCVkeHUh?=
BFTC-905	NI\CcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTFwMUO0OFkh\|ryP	NHjJTG5USU6JRWK=
HT	MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HMWmlEPTB;MT6xN\|Q4QCEQvF2=	NGDve29USU6JRWK=
CTB-1	NGLmOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfRSYprUUN3ME2xMlE1Ojl\|IN88US=>	NXPZVmd6W0GQR1XS
Hs-578-T	NXi1NVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\P[odKSzVyPUGuNVk2PjVizszN	MoWzV2FPT0WU
HuH-7	M{\V[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3MOlZKSzVyPUGuNlA6PDlizszN	NWCxV2lbW0GQR1XS
LB996-RCC	NX;0eItrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTFwMkKxO\|ch\|ryP	NFrhe2xUSU6JRWK=
KYSE-270	Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnvTWM2OD1zLkK5O\|M1KM7:TR?=	M{[zTXNCVkeHUh?=
A4-Fuk	NVm2SFRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLITWM2OD1zLkK5PVk{KM7:TR?=	NET3VotUSU6JRWK=
A498	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml32TWM2OD1zLkOwOFc1KM7:TR?=	NVu3d2FHW0GQR1XS
SK-MEL-1	M2KwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LsN2lEPTB;MT6zNFY4QSEQvF2=	NXHZVJF4W0GQR1XS
AU565	M2XR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTFwM{G4OlMh\|ryP	NGr1NnNUSU6JRWK=
Saos-2	NYPlT5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFwM{OyNFUh\|ryP	Mn\pV2FPT0WU
A549	NEH5bIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm5TWM2OD1zLkO5PVch\|ryP	NYPNRZlJW0GQR1XS
BFTC-909	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\xV2lEPTB;MT60N\|MxPSEQvF2=	NGnocYdUSU6JRWK=
MDA-MB-415	M3Pu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvhO\|hKSzVyPUGuOFg3QTJizszN	NWriUYlFW0GQR1XS
639-V	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnX1TWM2OD1zLkWwNlQ2KM7:TR?=	NFm1ZnVUSU6JRWK=
A704	NV;tZodIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXjTWM2OD1zLkWwO\|g2KM7:TR?=	NXfjN5pyW0GQR1XS
PANC-03-27	NIPpZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFwNUG0NFgh\|ryP	NX\vb5ZuW0GQR1XS
SK-MEL-28	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrQO3d2UUN3ME2xMlU3ODh3IN88US=>	NFPJeGZUSU6JRWK=
Ramos-2G6-4C10	NYjEcoVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjnRpJKSzVyPUGuOlA4PDZizszN	NIPyfVFUSU6JRWK=
HuP-T4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonWTWM2OD1zLk[wO\|c5KM7:TR?=	MnLkV2FPT0WU
VA-ES-BJ	NFXGcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHCTWM2OD1zLk[xNlch\|ryP	M{fRO3NCVkeHUh?=
EFM-19	NVLsXGpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTFwNkG4NUDPxE1?	MUHTRW5ITVJ?
G-401	NYfVe21yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXBcI5WUUN3ME2xMlYzOTZ2IN88US=>	M2mxXnNCVkeHUh?=
D-566MG	NV3HV4xbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfaXnVYUUN3ME2xMlYzPTNizszN	MV;TRW5ITVJ?
JVM-3	M{LVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTDS2tmUUN3ME2xMlY1QDd3IN88US=>	NEDjT5RUSU6JRWK=
TK10	MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojnTWM2OD1zLk[3NFg{KM7:TR?=	NXfCNlJbW0GQR1XS
BT-20	M4GxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTvTWM2OD1zLk[4PVAzKM7:TR?=	NXTmZVZ{W0GQR1XS
EGI-1	NXLncnJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTFwOES3NFEh\|ryP	MUXTRW5ITVJ?
EW-16	NELSc\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXLTWM2OD1zLki1NVgzKM7:TR?=	NVzF[HN2W0GQR1XS
NCI-H2228	M4jVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjxbo5KSzVyPUGuPFUzODNizszN	NYj5RY9MW0GQR1XS
BB49-HNC	NYfCZmRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\XTWM2OD1zLki4OlkzKM7:TR?=	NVO3eFc{W0GQR1XS
G-402	Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3vbW1KSzVyPUGuPFk4QTdizszN	MoHUV2FPT0WU
NCI-H526	MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7QR21uUUN3ME2xMlkyOzlizszN	M1i5UXNCVkeHUh?=
ME-180	NV\1SYZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTFwOUO0O\|ch\|ryP	M{PDVnNCVkeHUh?=
PFSK-1	NHfQ[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTFwOUS0OVgh\|ryP	M3nNeHNCVkeHUh?=
TYK-nu	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfVSmlFUUN3ME2xMlk2QDJ\|IN88US=>	Ml20V2FPT0WU
HOS	M4\TcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vjWWlEPTB;MT65O\|k1QCEQvF2=	MkfHV2FPT0WU
T98G	NF;DXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTFwOUmwNFYh\|ryP	NIDrflhUSU6JRWK=
SK-MES-1	M{[wPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn36TWM2OD1{LkCxN\|MzKM7:TR?=	NXnaXFRDW0GQR1XS
SNB75	MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPvPG1KSzVyPUKuNFE2PDFizszN	MoOzV2FPT0WU
LAMA-84	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1v6XWlEPTB;Mj6wNlY5QSEQvF2=	NX;oU3JbW0GQR1XS
CAL-39	NXLmOpN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljqTWM2OD1{LkCzNlgh\|ryP	MVPTRW5ITVJ?
LOXIMVI	NGnrUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\NTWM2OD1{LkC0NFg1KM7:TR?=	M1Tq[3NCVkeHUh?=
NH-12	M1H6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTLTWM2OD1{LkC1OFI1KM7:TR?=	M4LNWnNCVkeHUh?=
NCI-H1048	NVW0bo1oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV:zUlA2UUN3ME2yMlExPTJizszN	NVXGZXFFW0GQR1XS
KS-1	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fYXWlEPTB;Mj6xNVAxOSEQvF2=	NFHFVnJUSU6JRWK=
NCI-N87	NWn2N4psT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XzSmlEPTB;Mj6xN\|M5PCEQvF2=	NWPNZYJpW0GQR1XS
CHP-212	NXzuUVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJwMUi0OFIh\|ryP	MV7TRW5ITVJ?
HCC1419	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXmTWM2OD1{LkKxNVE2KM7:TR?=	NHz6cFRUSU6JRWK=
ES1	NGDOWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJwMkGzNlYh\|ryP	MlXtV2FPT0WU
NCI-H2030	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlT3TWM2OD1{LkK0NVI{KM7:TR?=	MmWwV2FPT0WU
EW-22	NIrCd4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvrTWM2OD1{LkK1NFY4KM7:TR?=	NWHuV5psW0GQR1XS
A431	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjEV3hKSzVyPUKuNlc{PTRizszN	NWLNU\|FYW0GQR1XS
SF126	NYjtOlNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTITWM2OD1{LkOwOlI2KM7:TR?=	MUfTRW5ITVJ?
SF295	Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPXTWM2OD1{LkOxOVI1KM7:TR?=	MXnTRW5ITVJ?
D-502MG	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvFUXZsUUN3ME2yMlMzPDZzIN88US=>	MYDTRW5ITVJ?
HCC2157	NIrTZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTOUpNKSzVyPUKuN\|I6OjdizszN	NXfMPZdoW0GQR1XS
D-283MED	M4i4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTWTWM2OD1{LkO1PVI3KM7:TR?=	M3i5fXNCVkeHUh?=
SNU-423	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LMO2lEPTB;Mj60NFE4OSEQvF2=	NUnpNYlsW0GQR1XS
SK-LU-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTJwNES1PFYh\|ryP	NYjZdYQ4W0GQR1XS
22RV1	MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWG3fG1MUUN3ME2yMlQ2PjF5IN88US=>	NEfrTotUSU6JRWK=
SW1088	MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTJwNEmyNVMh\|ryP	MknIV2FPT0WU
HT-3	NHnNfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3r2PGlEPTB;Mj60PVI2QSEQvF2=	MmSwV2FPT0WU
NCI-H1666	M1ztO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrCTWM2OD1{LkWxNVA1KM7:TR?=	MlT6V2FPT0WU
EM-2	NWrtcmdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTJwNUGxOlkh\|ryP	MmHkV2FPT0WU
SNU-449	NWrMW2s3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnOzTWM2OD1{LkW3NFE1KM7:TR?=	M2fNTXNCVkeHUh?=
786-0	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFj6O41KSzVyPUKuOVkzOzhizszN	M{XaNHNCVkeHUh?=
SKG-IIIa	M4\Rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTJwNkW5N\|kh\|ryP	NV3Nc5lkW0GQR1XS
MEL-HO	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDtb29KSzVyPUKuOlc3OzRizszN	MkPTV2FPT0WU
LCLC-97TM1	MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJwNkmyOlch\|ryP	MVjTRW5ITVJ?
MKN7	NHuzNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XRNWlEPTB;Mj63NFc2PCEQvF2=	MlziV2FPT0WU
5637	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7GOmJKSzVyPUKuO\|ExOzVizszN	NG[5eI5USU6JRWK=
HOP-92	M2nNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1OwN2lEPTB;Mj63OFcyPyEQvF2=	NULKdpE2W0GQR1XS
MDA-MB-157	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnDUGlKSzVyPUKuPFIxOjNizszN	NWrWUXUzW0GQR1XS
NB12	M{fYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvZTWM2OD1{Lki0PVE1KM7:TR?=	MX3TRW5ITVJ?
DMS-273	M2X2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4i3e2lEPTB;Mj64OlQ4KM7:TR?=	MnOzV2FPT0WU
HCC70	NUTUbo9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jqVmlEPTB;Mj64OlU5QSEQvF2=	M3K3fnNCVkeHUh?=
YKG-1	NX3pUlhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTNwMEO3PFch\|ryP	MlW4V2FPT0WU
NCI-H28	NFHxNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTNwMEWyPVEh\|ryP	NFnDSINUSU6JRWK=
HN	NFjXTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfubYJCUUN3ME2zMlA3PjN4IN88US=>	MVHTRW5ITVJ?
HT-1080	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTHTWM2OD1\|LkC4OlA3KM7:TR?=	MWjTRW5ITVJ?
HPAF-II	M1LmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fNbmlEPTB;Mz6xNFA3QCEQvF2=	NUjkdXZYW0GQR1XS
U-2-OS	NEm4ZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7SdXhzUUN3ME2zMlE{Pzh{IN88US=>	M33OR3NCVkeHUh?=
SNU-387	NHS1THdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFO4bmZKSzVyPUOuNVY{PjRizszN	MU\TRW5ITVJ?
Becker	NHnCOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\XeXdKSzVyPUOuNVY5ODhizszN	Mm\lV2FPT0WU
BHY	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETNZYZKSzVyPUOuNlU2PzFizszN	M3zodnNCVkeHUh?=
HTC-C3	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTNwMkmzOVIh\|ryP	MULTRW5ITVJ?
M14	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPHUm5MUUN3ME2zMlMxPjZ\|IN88US=>	M{TiSXNCVkeHUh?=
COR-L23	NXr3SohTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTNwM{eyO\|kh\|ryP	NULoNGprW0GQR1XS
C32	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDneYFvUUN3ME2zMlQyPTB6IN88US=>	NVroR4xwW0GQR1XS
Mewo	MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTNwNEKxPFIh\|ryP	NG\sSZFUSU6JRWK=
TE-8	M16zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\L[2JKSzVyPUOuOFgzPTlizszN	MWDTRW5ITVJ?
RPMI-2650	M{LYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfOb5JyUUN3ME2zMlYxPjN5IN88US=>	M3TZWHNCVkeHUh?=
AGS	NYDjR3VST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2C0fGlEPTB;Mz62NlQ3PCEQvF2=	M1\2TXNCVkeHUh?=
MZ2-MEL	M4ThNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Hub2lEPTB;Mz62OlE{QCEQvF2=	NEDT[FdUSU6JRWK=
Calu-3	MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\wTWM2OD1\|LkexNlg4KM7:TR?=	NX;2RnBMW0GQR1XS
SJSA-1	NYrGSWl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml35TWM2OD1\|LkexN\|E2KM7:TR?=	NGf4XJdUSU6JRWK=
SW962	NET3c29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkn2TWM2OD1\|LkeyOlM3KM7:TR?=	Mon1V2FPT0WU
PC-14	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHW1UJdKSzVyPUOuO\|MzOjJizszN	MWrTRW5ITVJ?
SW1573	NUTIcHN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHzSYdzUUN3ME2zMlc2OzR6IN88US=>	Mn\aV2FPT0WU
769-P	NFPvOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUL5elhpUUN3ME2zMlgzPzR\|IN88US=>	MULTRW5ITVJ?
KNS-62	NWDKfGI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoP4TWM2OD1\|LkmyN\|M5KM7:TR?=	Mn3NV2FPT0WU
NCI-H747	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTRwMEW2N\|gh\|ryP	NYrSc2tHW0GQR1XS
LN-405	NYfhXpdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfZTWM2OD12LkG1O\|I5KM7:TR?=	NH7FXYFUSU6JRWK=
OVCAR-8	NEO2RYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTRwMkK1OFMh\|ryP	NG\wSYNUSU6JRWK=
DMS-114	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1GxUWlEPTB;ND6yN\|g6OSEQvF2=	MYfTRW5ITVJ?
NCI-H2126	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXsTWM2OD12LkK0OVU5KM7:TR?=	NV\JTGdIW0GQR1XS
TCCSUP	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\1UGNKSzVyPUSuNlQ4QDhizszN	MWrTRW5ITVJ?
SK-N-FI	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHJXJo3UUN3ME20MlI2OzN{IN88US=>	MVjTRW5ITVJ?
HCE-4	M2PIcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYT3eXJVUUN3ME20MlI4OTl5IN88US=>	MX\TRW5ITVJ?
DK-MG	M33UOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTRwM{CzPUDPxE1?	M{TrOHNCVkeHUh?=
RO82-W-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTRwM{K1PFQh\|ryP	MUnTRW5ITVJ?
A2780	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPlNI14UUN3ME20MlM3Pjh{IN88US=>	NWD0PZNyW0GQR1XS
ETK-1	NVflRndvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfQTWM2OD12LkO3NFUzKM7:TR?=	MWTTRW5ITVJ?
FADU	NFfqb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTRwM{e0Olch\|ryP	NFnsV3pUSU6JRWK=
CAL-12T	NX7rdHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX[4N2U{UUN3ME20MlQyPDF\|IN88US=>	MV7TRW5ITVJ?
647-V	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTRwNESwNlIh\|ryP	MYrTRW5ITVJ?
TGBC1TKB	NYTEWotrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7vXXdXUUN3ME20MlQ2OTF\|IN88US=>	MlX3V2FPT0WU
LU-99A	NHP0TFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHpTWM2OD12LkS2NFYh\|ryP	MULTRW5ITVJ?
CAL-33	NYT6PJJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTRwNUK0OVYh\|ryP	NHTVSlhUSU6JRWK=
LU-134-A	NU\KNmtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHzTWM2OD12LkWyO\|Q2KM7:TR?=	MU\TRW5ITVJ?
NCI-H1355	NYPFUIo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrVOIZKSzVyPUSuOVUyPDZizszN	M3Tae3NCVkeHUh?=
RPMI-7951	NVzYXI0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoW0TWM2OD12LkW3NFAzKM7:TR?=	NUnaXZQ1W0GQR1XS
TE-1	M3;6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTRwNk[xOFMh\|ryP	NYPP[mJGW0GQR1XS
OE33	MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fKWGlEPTB;ND63NFUyOSEQvF2=	NIf2PJhUSU6JRWK=
CAL-51	NEXTOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzH[JJKSzVyPUSuO\|ExQDJizszN	M1fyNnNCVkeHUh?=
SW1783	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTRwN{WzNFgh\|ryP	NIHmZpJUSU6JRWK=
BT-474	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXneJA4UUN3ME20Mlc3Ozh2IN88US=>	MlPLV2FPT0WU
KYSE-520	MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTRwOEezPVIh\|ryP	MXHTRW5ITVJ?
8-MG-BA	NG\WW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTRwOEi1OVch\|ryP	MoXvV2FPT0WU
IA-LM	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTRwOUm0N\|Uh\|ryP	MWLTRW5ITVJ?
SW954	NVnyVI5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTRwOUm0OFMh\|ryP	MVrTRW5ITVJ?
RPMI-8226	NGnDXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPwPZI1UUN3ME21MlA2PDZzIN88US=>	NWraZnZZW0GQR1XS
MKN1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnwTWM2OD13LkC3PVI4KM7:TR?=	M{[0dHNCVkeHUh?=
A375	M3mxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:zRoFKSzVyPUWuNFkzPTZizszN	M{DkXnNCVkeHUh?=
8305C	M3LaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjMU285UUN3ME21MlA6QDh5IN88US=>	MUTTRW5ITVJ?
CAL-62	NIrOcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTUSJBKSzVyPUWuNVgzPTlizszN	M{nxZ3NCVkeHUh?=
NB10	NU\NRXZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXXWVNwUUN3ME21MlIzPzR2IN88US=>	NUHDTlZzW0GQR1XS
OC-314	NIjtSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHkelJRUUN3ME21MlM4PDR2IN88US=>	NFTtRldUSU6JRWK=
PSN1	NUXnfHI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIryRZRKSzVyPUWuN\|gzQDZizszN	M3XQR3NCVkeHUh?=
GR-ST	M1vGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\YZXluUUN3ME21MlM5OzJ{IN88US=>	M1rqZnNCVkeHUh?=
P12-ICHIKAWA	NV3OU3N{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVj5UJozUUN3ME21MlQxOSEQvF2=	MXPTRW5ITVJ?
NCI-H1092	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmq5TWM2OD13LkSxNVQ5KM7:TR?=	NWCyV\|dqW0GQR1XS
SCC-4	NXTRVIxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvMTWM2OD13LkSxN\|U2KM7:TR?=	NXfsNWY1W0GQR1XS
TE-6	NGnM[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPlVZJ5UUN3ME21MlQyQDF4IN88US=>	MXfTRW5ITVJ?
DOHH-2	MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjhcJBKSzVyPUWuOFIzPDhizszN	NVjOeVVsW0GQR1XS
SW684	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTVwNk[zPFUh\|ryP	MlfEV2FPT0WU
CP50-MEL-B	NH;1PIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\HemlEPTB;NT62PFY5PCEQvF2=	MnjwV2FPT0WU
UM-UC-3	NEmyZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7VTWM2OD13LkeyNlMyKM7:TR?=	M1zwXnNCVkeHUh?=
LC-2-ad	MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWC5NmFEUUN3ME21Mlc5OjVzIN88US=>	NXPFVZBYW0GQR1XS
PC-3	NWHFTYhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTVwOUG2NVUh\|ryP	NVrTe4oyW0GQR1XS
CAN	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTVwOUK4NkDPxE1?	MUPTRW5ITVJ?
ESS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTyTWM2OD13Lkm3PFY6KM7:TR?=	MnH3V2FPT0WU
ATN-1	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PTWmlEPTB;Nj6wOVU3QCEQvF2=	Ml7kV2FPT0WU
BxPC-3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PJN2lEPTB;Nj6wPFIyQSEQvF2=	MVnTRW5ITVJ?
KYSE-150	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13kZmlEPTB;Nj6xNlQ4PiEQvF2=	MU\TRW5ITVJ?
RPMI-8866	NYr2SG57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LzTGlEPTB;Nj6xPVE3OyEQvF2=	Mnj3V2FPT0WU
SW780	NGnVVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV:4eoxlUUN3ME22MlIxPDJizszN	MmTlV2FPT0WU
A388	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7xTWM2OD14LkKzNVE2KM7:TR?=	MY\TRW5ITVJ?
NCI-H1437	NYnGdIxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3kTWM2OD14LkK0NFc{KM7:TR?=	NFPMRldUSU6JRWK=
NCI-H1755	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LYe2lEPTB;Nj6zOlYyOiEQvF2=	NVzUWVlCW0GQR1XS
LS-123	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfCTWM2OD14LkSwOVIyKM7:TR?=	Mke4V2FPT0WU
CaR-1	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\BTHRuUUN3ME22MlQ3Ozd\|IN88US=>	MW\TRW5ITVJ?
RT-112	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33ZOGlEPTB;Nj62NFM{QCEQvF2=	M4\wU3NCVkeHUh?=
CGT	M{\GZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rnb2lEPTB;Nj63N\|Y5OSEQvF2=	MYnTRW5ITVJ?
SW626	MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnJXGlKSzVyPU[uO\|M6PDZizszN	NEDaRoJUSU6JRWK=
AsPC-1	NYfRdoZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTZwN{S1NFch\|ryP	MYXTRW5ITVJ?
SBC-5	NF7PbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH74TIZKSzVyPU[uPVczQTdizszN	MV;TRW5ITVJ?
SF539	NV7DVXF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTZwOUmzN\|Mh\|ryP	NWXvWIo2W0GQR1XS
TI-73	NHTYXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTJVGt2UUN3ME23MlA3Ojh3IN88US=>	NVHW[XV6W0GQR1XS
MHH-ES-1	M2jkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF[3TmNKSzVyPUeuNFc4PjJizszN	NYPmNFllW0GQR1XS
KYSE-510	NHrlN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX36VZo4UUN3ME23MlA5PDN{IN88US=>	Ml;lV2FPT0WU
EW-1	M3;3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTdwM{[5PVYh\|ryP	NGHReJpUSU6JRWK=
SK-OV-3	Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTdwM{m0N\|Ih\|ryP	M3LKSnNCVkeHUh?=
MC-IXC	MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWntNYZUUUN3ME23MlQyQTd{IN88US=>	NUnweW1oW0GQR1XS
HSC-2	MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;oTW5KSzVyPUeuOFI4ODVizszN	MY\TRW5ITVJ?
NCI-H2342	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\vTWM2OD15LkWxOFkh\|ryP	Ml;FV2FPT0WU
NCI-H1792	NVTmU\|NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofDTWM2OD15LkWxO\|EyKM7:TR?=	MoHrV2FPT0WU
HT-1376	NGrvdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTdwOEe3O\|gh\|ryP	MlHXV2FPT0WU
EW-13	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTS[2tVUUN3ME23Mlg6QTd5IN88US=>	M2XaU3NCVkeHUh?=
no-11	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTvPXU6UUN3ME23MlkxOTd2IN88US=>	NYXubFQ3W0GQR1XS
Daoy	NVfEPGwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPCVoxlUUN3ME23Mlk1OzJzIN88US=>	NWn4XpZFW0GQR1XS
COLO-800	NHrnPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTzb4xKSzVyPUiuNFQyPjJizszN	MXfTRW5ITVJ?
GB-1	NWjlOW5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;KVG1KSzVyPUiuNFY2PjVizszN	Mnr2V2FPT0WU
SJRH30	NEfPXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LpN2lEPTB;OD6xOVg4QCEQvF2=	MnPpV2FPT0WU
NCI-H2291	NGq4RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVf2flVsUUN3ME24MlI6OTh5IN88US=>	MYPTRW5ITVJ?
J82	NYT4OlNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXHOYI3UUN3ME24MlI6PDlzIN88US=>	M{nKWHNCVkeHUh?=
NCI-H596	M1jkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjkNmluUUN3ME24MlMyPDV\|IN88US=>	MWnTRW5ITVJ?
RERF-LC-MS	NGPJfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvxb4FKSzVyPUiuN\|Q5PTZizszN	NG[4XIRUSU6JRWK=
RH-18	MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTpTWM2OD16LkO1NFQ3KM7:TR?=	MXzTRW5ITVJ?
SW48	M3v1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3mS2NKSzVyPUiuOVk1PTNizszN	NGPiTFZUSU6JRWK=
RD	NGWybnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1iwbGlEPTB;OD61PVM6OSEQvF2=	Mn3zV2FPT0WU
MS-1	NWO5XndDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRThwNkGzPFch\|ryP	NWiwU2llW0GQR1XS
ES6	M{PNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\wdGlEPTB;OD63N\|EyQSEQvF2=	NV3CRYp2W0GQR1XS
TE-12	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\zZndKSzVyPUiuO\|c2ODVizszN	NELzenVUSU6JRWK=
DBTRG-05MG	NHvieWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHCUHdKSzVyPUiuPVEzOTdizszN	MoWzV2FPT0WU
KINGS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGn5NGhKSzVyPUiuPVI6OzhizszN	MXHTRW5ITVJ?
HLE	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRThwOUO3PFUh\|ryP	MnTJV2FPT0WU
MHH-NB-11	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETGd3pKSzVyPUmuNFE5OzlizszN	M2PCZ3NCVkeHUh?=
U-87-MG	Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLibFZNUUN3ME25MlI1OzJzIN88US=>	NGr4WYhUSU6JRWK=
MN-60	M4TMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFz1fXhKSzVyPUmuNlQ2PDJizszN	NHPYXnZUSU6JRWK=
SAS	NWXBPINjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYi0WFFRUUN3ME25MlI2PThzIN88US=>	NHvKbW9USU6JRWK=
NCI-H446	MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTlwM{[xJO69VQ>?	MojnV2FPT0WU
C-33-A	NIDtZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTlwNEO5PFgh\|ryP	MYjTRW5ITVJ?
RXF393	NX7qdIRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4noV2lEPTB;OT60O\|AxOiEQvF2=	NH7oZZZUSU6JRWK=
CGTH-W-1	NUfrOFV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXKfnVKSzVyPUmuOFk{QDRizszN	MVzTRW5ITVJ?
RCM-1	NHm4N4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV:0TlZjUUN3ME25MlY{QDBzIN88US=>	NEnzZoJUSU6JRWK=
SN12C	MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXtVnZxUUN3ME25MlY2OzN6IN88US=>	NIrhNopUSU6JRWK=
KLE	NVTqWFNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37MSGlEPTB;OT63NFAxQSEQvF2=	M{jCNHNCVkeHUh?=
EFO-21	NHr0dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFn5b\|VKSzVyPUmuO\|c{QDJizszN	MWXTRW5ITVJ?
KYSE-70	NYCxb3ViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jwO2lEPTB;OT64PFAyOSEQvF2=	MXjTRW5ITVJ?
D-247MG	NWrvdJpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFyLkC1Olgh\|ryP	MmXOV2FPT0WU
MPP-89	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vlNWlEPTB;MUCuNFk1PiEQvF2=	MXnTRW5ITVJ?
RVH-421	NHTBPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7pbY9mUUN3ME2xNE4yPTB3IN88US=>	NWDGOJFRW0GQR1XS
NCI-H460	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEm5bY9KSzVyPUGwMlI5ODZizszN	MkPwV2FPT0WU
NOMO-1	Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4[zTWlEPTB;MUCuN\|U{OiEQvF2=	NX\WTZlNW0GQR1XS
DEL	NHHkenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPSNFdKSzVyPUGwMlM4QTRizszN	MVjTRW5ITVJ?
HT55	NXzEN2dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHj6XVhKSzVyPUGwMlYzODVizszN	M4HzVnNCVkeHUh?=
MC116	MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITPdlJKSzVyPUGwMlY3PTVizszN	M1fNWHNCVkeHUh?=
BB30-HNC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1j2XWlEPTB;MUCuOlY6KM7:TR?=	MYTTRW5ITVJ?
DJM-1	NFHXd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mly4TWM2OD1zMD62PVQ6KM7:TR?=	M1LGcnNCVkeHUh?=
ZR-75-30	M1G5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M164e2lEPTB;MUCuPVQ1OSEQvF2=	NXzrSm44W0GQR1XS
U-118-MG	NEHs[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjsZotVUUN3ME2xNE46QDl4IN88US=>	MmDZV2FPT0WU
MSTO-211H	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PIOGlEPTB;MUGuNFcyPiEQvF2=	NVfhXndHW0GQR1XS
SW837	MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXXd3FKSzVyPUGxMlA6PDlizszN	NHm4W4ZUSU6JRWK=
HuCCT1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTFzLkGyPFEh\|ryP	Ml\IV2FPT0WU
RCC10RGB	NHnJS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTFzLkGzOUDPxE1?	MYrTRW5ITVJ?
NMC-G1	MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;yTnhKSzVyPUGxMlE1QTNizszN	M4jXXHNCVkeHUh?=
NCI-H650	NF7PXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEK3SYpKSzVyPUGxMlM4QTRizszN	M1XRXHNCVkeHUh?=
HEC-1	NYTwVpBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\wTWM2OD1zMT60N\|I5KM7:TR?=	MXLTRW5ITVJ?
DU-4475	NEHxcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PvN2lEPTB;MUGuO\|M6OyEQvF2=	NHf2U3VUSU6JRWK=
DSH1	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWD0bWNPUUN3ME2xNU44PjB4IN88US=>	Mn;IV2FPT0WU
HCC1569	MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFzLke2O\|gh\|ryP	MXPTRW5ITVJ?
HCC1187	NIHwdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTFzLki1PFgh\|ryP	MUPTRW5ITVJ?
EW-11	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jOd2lEPTB;MUGuPVQ4PCEQvF2=	M2q0[HNCVkeHUh?=
LB2518-MEL	NH7xZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF{LkC1PUDPxE1?	NFfpOoNUSU6JRWK=
KALS-1	M3iydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTF{Lki1OVMh\|ryP	MoL5V2FPT0WU
8505C	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTDUIRKSzVyPUGyMlg5PSEQvF2=	M2XuXnNCVkeHUh?=
SK-N-DZ	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDabVl1UUN3ME2xN{4xPDV\|IN88US=>	M4n5OnNCVkeHUh?=
CHP-134	Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTIVnNJUUN3ME2xN{4yOTV6IN88US=>	NX7sNWpjW0GQR1XS
HCE-T	M3jtfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHaTWM2OD1zMz6yN\|Y1KM7:TR?=	NV;yPVA6W0GQR1XS
LB-831-BLC	NGCyfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3iw[mlEPTB;MUOuOlI1PiEQvF2=	NVTL[GZLW0GQR1XS
OVCAR-4	M3rvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV23bopXUUN3ME2xN{43PTJ2IN88US=>	NHXlNGtUSU6JRWK=
SW756	NXTQS4E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPaTWM2OD1zMz63NlQ3KM7:TR?=	M2i2UHNCVkeHUh?=
OCUB-M	NU\uUnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvrTWM2OD1zMz64NVU3KM7:TR?=	NIDvc3dUSU6JRWK=
SW982	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTwOJRKSzVyPUGzMlgzPzZizszN	M2DIZ3NCVkeHUh?=
DB	NXPXV45ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUD4e4hlUUN3ME2xN{45Ozh2IN88US=>	NU\CSmd5W0GQR1XS
H-EMC-SS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTF\|LkmxN\|kh\|ryP	NWDwTVFzW0GQR1XS
VMRC-RCZ	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fQVGlEPTB;MUSuNFAyPSEQvF2=	NG\DV2NUSU6JRWK=
CAKI-1	NWP2WVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTF2LkCxN\|Ih\|ryP	MkPyV2FPT0WU
GI-1	NV\2eHJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYWwR4cxUUN3ME2xOE4xPjV6IN88US=>	NGHybI9USU6JRWK=
Ca9-22	NVPWR4JxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LjVWlEPTB;MUSuOlA2PCEQvF2=	NXvwXm5wW0GQR1XS
TE-5	NGDLNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTF2LkeyNFgh\|ryP	MV\TRW5ITVJ?
EFO-27	NX6wZYg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfhTWM2OD1zND63OlIzKM7:TR?=	MkXpV2FPT0WU
CAL-72	NX:3O5c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUntUJBYUUN3ME2xOE44Pzh\|IN88US=>	MWHTRW5ITVJ?
GP5d	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFz6[nBKSzVyPUG1MlA1PzRizszN	MYTTRW5ITVJ?
CAS-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDhTI4{UUN3ME2xOU4xPjZizszN	MVTTRW5ITVJ?
A2058	NVjnZo9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXOTWM2OD1zNT61OlM5KM7:TR?=	M2W4fHNCVkeHUh?=
PANC-08-13	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DNNGlEPTB;MUWuOlg2QSEQvF2=	NWGxbXozW0GQR1XS
Detroit562	NWOxTHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nK[mlEPTB;MUWuPVE{QSEQvF2=	MnrZV2FPT0WU
PANC-10-05	M{[zW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH2xenRKSzVyPUG2MlA5OjFizszN	M4X4ZXNCVkeHUh?=
KOSC-2	NX3ofY9mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTF4LkGxNlUh\|ryP	MnrFV2FPT0WU
GT3TKB	NYnJPVc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1L1O2lEPTB;MU[uNVk5OSEQvF2=	M3LGWnNCVkeHUh?=
KM-H2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTF4LkO2OFYh\|ryP	NGfPV3dUSU6JRWK=
LB771-HNC	MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{C2eGlEPTB;MU[uOFQzOiEQvF2=	MlXLV2FPT0WU
SF268	MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3K1SmlEPTB;MU[uOFUzKM7:TR?=	M1rtO3NCVkeHUh?=
OE19	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHyeHhQUUN3ME2xOk42OjRizszN	NFfHSZVUSU6JRWK=
MLMA	NUXWT3lsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfFTWM2OD1zNj61OVcyKM7:TR?=	NFyxbm9USU6JRWK=
MDA-MB-231	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnv3TWM2OD1zNj63NVM3KM7:TR?=	NYTnXZB{W0GQR1XS
TGW	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTMT\|dVUUN3ME2xOk45OTB{IN88US=>	M2PONXNCVkeHUh?=
MDA-MB-453	NHTYS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33FXWlEPTB;MUeuNFAxOyEQvF2=	NFq5WplUSU6JRWK=
SNU-C2B	NH;mPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTF5LkCyN\|ch\|ryP	M{P0dnNCVkeHUh?=
A427	NVmwPHlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTF5LkKzN\|Qh\|ryP	NVKxRo5{W0GQR1XS
SK-MEL-2	NY[5[Yg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHpTWM2OD1zNz6zNlE{KM7:TR?=	NGL6d2tUSU6JRWK=
KURAMOCHI	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nBcGlEPTB;MUeuN\|g6PyEQvF2=	NXjtb5N7W0GQR1XS
IST-MEL1	NFi4dXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVn2ZmtyUUN3ME2xO{46OTh{IN88US=>	NEHQWphUSU6JRWK=
NCI-H1793	NXTpeFZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkOzTWM2OD1zOD6xOVgyKM7:TR?=	Ml\DV2FPT0WU
HCC1395	MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTF6LkW2NVEh\|ryP	NVPyNIlvW0GQR1XS
NUGC-3	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXr5ZpRNUUN3ME2xPE43PTh2IN88US=>	Mlj0V2FPT0WU
BB65-RCC	M{nNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIi1OZFKSzVyPUG4MlY3QSEQvF2=	M1zuZnNCVkeHUh?=
RMG-I	NXy5TXBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTF6LkezPFIh\|ryP	NGnqZW9USU6JRWK=
LS-513	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXaTWM2OD1zOD65NlI5KM7:TR?=	MnjIV2FPT0WU
MFM-223	NHLvRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjSTWM2OD1zOT6wO\|E3KM7:TR?=	MXzTRW5ITVJ?
NCI-H727	MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoryTWM2OD1zOT6zNlk2KM7:TR?=	M4j3S3NCVkeHUh?=
KP-4	NG\nW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXWVFNKSzVyPUG5Mlg2OzFizszN	MlXGV2FPT0WU
NB13	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXPfYJKSzVyPUG5Mlg5OzlizszN	NUPiPI41W0GQR1XS
UACC-893	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nQZ2lEPTB;MUmuPVc2PyEQvF2=	Mmf0V2FPT0WU
HT-1197	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlO3TWM2OD1{MD6yPVU5KM7:TR?=	NVXGZppsW0GQR1XS
NCI-H2029	M1;UT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIG2Z4JKSzVyPUKwMlMzPjZizszN	M2\FdXNCVkeHUh?=
GI-ME-N	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\DeWlEPTB;MkCuN\|M4OyEQvF2=	M1\5NXNCVkeHUh?=
OVCAR-3	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTJyLkW4NlIh\|ryP	NUPBSVAxW0GQR1XS
HD-MY-Z	NVHROVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjXWpdNUUN3ME2yNU4{Pjl4IN88US=>	MUHTRW5ITVJ?
NTERA-S-cl-D1	MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJzLk[3NlIh\|ryP	MWnTRW5ITVJ?
SCH	M3PzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLv[nFKSzVyPUKyMlQ6PiEQvF2=	MVjTRW5ITVJ?
KARPAS-299	NXzrRo51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW[2Z25LUUN3ME2yN{4{QDh5IN88US=>	NX3GW\|hjW0GQR1XS
NCI-H1650	MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfNb4RKSzVyPUKzMlkzPDFizszN	MmjDV2FPT0WU
ACHN	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorvTWM2OD1{ND60OlU3KM7:TR?=	NWqwN4ZxW0GQR1XS
M059J	NH:2W\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTJ2LkW2N\|Qh\|ryP	MnjYV2FPT0WU
AM-38	Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HmSWlEPTB;MkWuOFgyKM7:TR?=	NYHUWG1CW0GQR1XS
KG-1	M3vMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWX2bHRGUUN3ME2yOU42PDl2IN88US=>	MXHTRW5ITVJ?
COLO-824	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTNOnRKSzVyPUK1MlU2QTlizszN	M4L3U3NCVkeHUh?=
NCI-H1155	NFXUZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M32yNWlEPTB;MkWuOVg1PyEQvF2=	MUPTRW5ITVJ?
NCI-H441	NYLkXWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJ3Lke0OlUh\|ryP	MnLaV2FPT0WU
J-RT3-T3-5	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHReZFsUUN3ME2yOk4{ODJ5IN88US=>	NX3ve5AyW0GQR1XS
JEG-3	NUmxVFR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HSWmlEPTB;Mk[uOlgxPSEQvF2=	NHvVdVJUSU6JRWK=
RKO	M1vDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTJ4Lke2N\|Ih\|ryP	MXnTRW5ITVJ?
CAL-85-1	NEXEbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXG5XZVTUUN3ME2yO{4zOTF6IN88US=>	M17veHNCVkeHUh?=
CAL-120	M1joPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVn2[oVyUUN3ME2yO{43QTF2IN88US=>	M3nRVXNCVkeHUh?=
NCI-H2452	Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vodmlEPTB;MkeuO\|cyPiEQvF2=	Mn3WV2FPT0WU
NCI-H1395	NU\wSXk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmK0TWM2OD1{Nz63PFM{KM7:TR?=	NEXXOlZUSU6JRWK=
KYSE-450	NWTDOYpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzVNIlKSzVyPUK3Mlk5PjJizszN	MWTTRW5ITVJ?
S-117	NIHrfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTJ7LkO4OVch\|ryP	NXX5OVd4W0GQR1XS
SW13	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTJ7Lki1NVkh\|ryP	NInS[2VUSU6JRWK=
ES3	NG[weWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTNyLkO3N\|Mh\|ryP	NWLIN5kxW0GQR1XS
HCT-116	NHX3PG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTNyLkW1OVQh\|ryP	MoLHV2FPT0WU
NCI-H1693	NF:y[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV64PVdWUUN3ME2zNE42QTR{IN88US=>	NHHiZ\|RUSU6JRWK=
VM-CUB-1	MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nkPGlEPTB;M{CuOlQyOyEQvF2=	NX7OToZ3W0GQR1XS
NCI-H2170	NXXZZmxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1naZ2lEPTB;M{GuOVc5PCEQvF2=	NH7uRllUSU6JRWK=
ALL-PO	M2Did2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInqfJJKSzVyPUOxMlg1OjhizszN	M{S1SnNCVkeHUh?=
NCI-H661	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fZVWlEPTB;M{KuNFYzOyEQvF2=	MYPTRW5ITVJ?
NCI-H2347	NInkT\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PzVGlEPTB;M{KuOFg{PyEQvF2=	MYfTRW5ITVJ?
FTC-133	NFHWbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PZdmlEPTB;M{KuO\|A3KM7:TR?=	NHvoOmJUSU6JRWK=
COLO-829	NIrsSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUj2VZdjUUN3ME2zN{4{PDZ5IN88US=>	MmK1V2FPT0WU
GOTO	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{C2SmlEPTB;M{OuOVI2QCEQvF2=	NGjGcWdUSU6JRWK=
YAPC	NFywVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHGNo9KSzVyPUOzMlgyPTlizszN	MVrTRW5ITVJ?
LCLC-103H	M2WyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrDdIxKSzVyPUO0MlE3OjRizszN	NXTSbI1RW0GQR1XS
SiHa	NIPZNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTN2LkO4NVch\|ryP	MWTTRW5ITVJ?
LK-2	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LGU2lEPTB;M{SuOVcxQCEQvF2=	NHHw[Y9USU6JRWK=
KP-N-YS	M3Tke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTN2LkeyNFIh\|ryP	MUnTRW5ITVJ?
NCI-SNU-1	MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLGVZVKSzVyPUO1MlE4QSEQvF2=	MlzMV2FPT0WU
KNS-81-FD	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLJWo83UUN3ME2zOU43PjNizszN	NF2xfXVUSU6JRWK=
SCC-9	M3LZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTN4LkexOFYh\|ryP	MlrPV2FPT0WU
SH-4	NXvNVnM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\hTWM2OD1\|Nj63N{DPxE1?	MXLTRW5ITVJ?
HCC-1954	M4P3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEO4bYtKSzVyPUO3MlI4OjlizszN	MorHV2FPT0WU
BALL-1	NVnQXmVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGr3V4ZKSzVyPUO3MlU{OTZizszN	NXzmdHdoW0GQR1XS
BE-13	M3[yfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHwTWM2OD1\|Nz63NFE5KM7:TR?=	MXPTRW5ITVJ?
COLO-678	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTN5Lkm0N\|ch\|ryP	MYHTRW5ITVJ?
SK-MEL-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPQTWM2OD1\|OD6yN\|k4KM7:TR?=	MnPoV2FPT0WU
OAW-28	NYS1bFlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfhfXd7UUN3ME2zPE43OzlizszN	NIXr[W5USU6JRWK=
CAMA-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTN6Lkm2PVEh\|ryP	MV\TRW5ITVJ?
C2BBe1	NHPDS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDKTWM2OD1\|OT64NVgh\|ryP	MlL6V2FPT0WU
A3-KAW	MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HCWmlEPTB;NECuN\|Y3OSEQvF2=	MnnVV2FPT0WU
SK-MEL-24	Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml35TWM2OD12MD61PVMyKM7:TR?=	NFzYV5VUSU6JRWK=
KYSE-140	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\Zcm1KSzVyPUSwMlcyPjVizszN	MYHTRW5ITVJ?
MOLT-16	MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTRzLkG1N\|Yh\|ryP	NXnOXXRqW0GQR1XS
CFPAC-1	M1jzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXK5O\|lGUUN3ME20Nk42OjFzIN88US=>	MUjTRW5ITVJ?
NB14	NVvR[2ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7hTWM2OD12Mj63NFI4KM7:TR?=	NHzTWVZUSU6JRWK=
COLO-792	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DFOWlEPTB;NEKuPFk3OSEQvF2=	NEnJPG5USU6JRWK=
RH-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\seo9KSzVyPUSzMlQ5OzZizszN	NXjldpdvW0GQR1XS
NCI-H522	NXjnVWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTR2LkO1Olgh\|ryP	NG\jZ2VUSU6JRWK=
Ca-Ski	MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTR2LkixNVQh\|ryP	NXW2e\|d{W0GQR1XS
KGN	NV\4[YVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfYeY5KSzVyPUS4MlMxPjNizszN	NWm1XnpZW0GQR1XS
UACC-62	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjzbIJ1UUN3ME20PE41ODd{IN88US=>	Mlj0V2FPT0WU
NCI-H358	MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTR7LkOwNVgh\|ryP	NH;Tdo9USU6JRWK=
LS-411N	NH[1T2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfHTWM2OD12OT6zNVE5KM7:TR?=	MVjTRW5ITVJ?
IST-MES1	NF7UdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnVW2ZKSzVyPUS5MlU3OjVizszN	MVnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	- Collapse Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	RG7321
Smiles	CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Dactolisib (BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)